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Abstract
Drug repositioning helps fully explore indications for marketed drugs and clinical candidates. Here we show that the clinical
side-effects (SEs) provide a human phenotypic profile for the drug, and this profile can suggest additional disease
indications. We extracted 3,175 SE-disease relationships by combining the SE-drug relationships from drug labels and the
drug-disease relationships from PharmGKB. Many relationships provide explicit repositioning hypotheses, such as drugs
causing hypoglycemia are potential candidates for diabetes. We built Naı ¨ve Bayes models to predict indications for 145
diseases using the SEs as features. The AUC was above 0.8 in 92% of these models. The method was extended to predict
indications for clinical compounds, 36% of the models achieved AUC above 0.7. This suggests that closer attention should
be paid to the SEs observed in trials not just to evaluate the harmful effects, but also to rationally explore the repositioning
potential based on this ‘‘clinical phenotypic assay’’.
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Introduction
Repositioning helps fully explore the indications of marketed
drugs and clinical candidates [1]; however, most successful stories
of repositioning are based on serendipity and not systematic
analysis [2]. In silico methodologies have helped in mining the
drug’s off-target effects [3,4,5,6,7,8], off-system effects (such as, off-
target related gene expression perturbation or downstream
pathways) [9,10,11,12,13] and off-phenotypes (i.e. adverse drug
reactions [14,15] or new indication) providing new hypotheses to
reposition the drug. These strategies focus primarily on using
preclinical information. Unfortunately, clinical therapeutic effects
are not always consistent with preclinical outcomes [16].
Recently, a systematic analysis observed that phenotypic
screening exceeded target-based approaches in discovering first-
in-class small-molecule drugs [17]. Clinical phenotypic informa-
tion comes from actual patient data, which mimics a phenotypic
‘‘screen’’ of the drug effects on human, and can directly help
rational drug repositioning. For example, Chiang and Butte
suggested new indications for a drug based on its existing
therapeutic effect [18]. In our study, however, we utilize the rich
information from the clinical side-effects (SEs), which are usually
regarded only as unwanted effects to suggest new indications for a
drug. For instance, hypotension is an unfavorable SE of some drugs.
However, those drugs may also act as anti-hypertensives, if we
utilize this SE by controlling the dosing, improving the
formulation and choosing the sub-population etc.
The rationale for this strategy is that SEs and indications are
both measurable behavioral or physiological changes in response
to the treatment, and if drugs treating a disease share the same SE,
there might be some underlying mechanism-of-action (MOA)
linking this disease and the SE. The SE may thus serve as a
phenotypic ‘‘biomarker’’ for this disease. Furthermore, both
therapeutic and side effects are observations on human subjects,
as opposed to animal models, so there is less of a translational
issue. The methodology of Drug Repositioning based on the Side-
Effectome (DRoSEf) is discussed in this study. The basic
hypothesis is that if the SEs associated with a drug D are also
induced by many of the drugs treating disease X, then drug D
should be evaluated as a candidate for treating disease X. We
constructed a database of disease-SE associations from drug-SE
data extracted from drug labels by SIDER and drug-disease
relationships from PharmGKB (Table S1). Researchers, who
observe an unexpected effect in their clinical trial can query the
database for other diseases associated with this phenotype. This
would suggest alternative indications for the drug. Using this
approach, we predict new indications for marketed drugs. In
addition, we built QSAR models to predict side effects based on
the compound structure. For 4,200 candidate drugs with no
available clinical SE information, we were able to combine the
above QSAR models with the SE-disease models to predict new
indications.
Results
Identification of the disease-side effect associations
Both disease-drug associations and drug-SE associations are
required to infer disease-SE associations. We extracted the
indications of drugs from PharmGKB to provide the disease-drug
associations [19]. The SEs printed on the drug label provide
consistent and reliable data as these are summarized from large
clinical trials, and the drug label is approved and standardized by
regulatory agencies. The SIDER database [4], which has been
used to predict drug off-targets provides a mapping extracted from
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21drug labels of 888 approved drugs to 584 side effects. These 888
drugs map to 303 drugs and 145 diseases in PharmGKB. We used
the binary fact of the SE’s presence on the drug label as listed in
SIDER. Similar to generating gene-SE associations in ref [20], we
inferred disease-SE associations by counting the number of the
drugs listing or not listing a SE when indicated or not indicated for
a disease, generating a confusion matrix as shown in Fig. 1A. The
association strength of a disease-SE pair is measured using
multiple criteria, including the Matthews correlation coefficient
(MCC), sensitivity (sn) and specificity (sp). We computed 84,680
confusion matrices for each pair of 145 diseases and 584 SEs.
3,175 (3.75%) of these associations (Table S1) were considered
possibly informative (using multiple criteria as described in
Methods).
We investigated a few of the 3,175 associations to understand
what these associations implied and how they could be used to
suggest new indications. Some of the associations have an explicit
explanation based on the current knowledge of the MOA
(Table 1). The SE positive Antinuclear Antibodies (ANA)indicates the
presence of autoimmune antibodies and appears to be associated
with stroke. It is the SE shared by drugs treating stroke, mainly
ticlopidine and several angiotensin-converting enzyme (ACE)
inhibitors. Stroke itself, is associated with severe immune
suppression [21]. Thus, conceivably drugs that are associated
with increasing immune response in terms of positive ANA may help
stroke patients, though of course an autoimmune response is not
desirable. Overall, 50% of the drugs treating stroke list this SE,
whereas only 2% of the drugs not indicated for stroke list positive
ANA as a SE. This 2% (often termed false positives) includes
several statins and ramipril (Table 1). Several statins are
associated with positive ANA, but are not indicated for stroke.
However, a meta-analysis of 120,000 patients across 42 trials
showed that statin therapy provides protection for all-cause
mortality and nonhemorrhagic strokes [22]. Ramipril, which also
lists positive ANA as a SE, showed a 32% risk reduction for stroke
[23]. DRoSEf is suggesting that the immune related SEs of these
drugs directly indicate their use for stroke, and this has also
recently been recognized experimentally [23].
Cytomegalovirus infection is a sign of a weakened immune
system [24]. Drugs that reduce immune response are often used to
prevent transplant rejection, thus drugs that list increased
cytomegalovirus (CMV) infections as a SE may be good candidates
Figure 1. Constructing and visualization of the disease-SE associations. a) Confusion matrix of using SE priapism to predict Parkinson
Disease. PD: Parkinson Disease; MCC: Matthews correlation coefficient; TP, FP, TN and FN stand for true positives, false positives, true negatives and
false negatives respectively. This confusion matrix represents one disease-SE pair. b) The overall layout of the disease-SE network. Diseases and SEs
are shown in red and white circles respectively. The edge color and the width indicate the association strength as measured by MCC. The
neuropsychiatric, neoplasm, circulatory- system disease dominated clusters are highlighted in yellow, red and grey rectangles respectively. c)
Neuropsychiatric disease-dominated cluster. The SE tardive dyskinesia and priapism is highlighted in orange. The MCC for PD-priapism pair is 0.47
according to the confusion matrix in a) and is visualized as an orange line (see black arrow from a) to c)) . d) Sample MCC, sensitivity and specificity
measures for using priapism to predict diseases. For example, 86% of the drugs that treat obsessive-compulsive disorder (OCD) list priapism as a side
effect; whereas only 7% (1-sp) of the drugs not reported to treat OCD list this SE.
doi:10.1371/journal.pone.0028025.g001
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drug lists CMV infections as a SE. As a dihydrofolic acid reductase
inhibitor, it is officially used as an antineoplastic, but has been
reported for the off-label use of preventing transplant rejection
[25].
DRoSEf suggests that drugs that list porphyria as an SE may act
as antidiabetics. In a study of 328 Swedish patients with porphyria,
the 16 patients that developed diabetes all had their porphyria
symptoms resolved [26]. Valproic acid, pyrazinamide, naproxen,
and estradiol all list porphyria as a SE but are not indicated for
diabetes. Valproic acid is an anticonvulsant and a recent study
found it effective in lowering blood glucose levels in Wfs1 knockout
mice [27]. Pyrazinamide is an anti-tuberculosis agent, and type II
diabetes is a known risk factor for tuberculosis [28]. In mice,
naproxen is used as a tool to delay or prevent the development of
type II diabetes from a pre-diabetic condition [29]. In a double-
blinded, randomized placebo controlled clinical trial on women
with type II diabetes, oral estradiol significantly decreased fasting
glucose [30].
Drugs that list delusions as a side effect may help with depression.
Cabergoline, an ergot derivative that causes delusions,i sa
dopamine agonist that has an antidepressant-like property [31].
The dopamine receptor agonist pergolide has shown antidepres-
sant effects in Parkinson patients [32]. Hyperacusis is a medical
condition associated with hypersensitivity to certain frequency
ranges of sounds. Phenytoin is a known anticonvulsant with
hyperacusis as a listed side effect, and DRoSEf suggests a potential
utility for treating depression. In fact, a small clinical trial found
equivalent therapeutic effects between phenytoin and fluoxetine in
treating depression [33]. Modafinil is a drug for narcolepsy and is
also potentially effective in combination with fluoxetine to treat
depression [34].
Constitutional symptoms are a listed SE for many antineoplasm
drugs. An anti-HIV drug nevirapine also lists constitutional symptoms
as a SE. Nevirapine has previously been suggested as a treatment
for human hormone-refractory prostate carcinoma [35].
In fact, 27% of the ‘‘false positive’’ drugs-disease association
(Table S2) suggested by DRoSEf have at least one article in
PubMed of publication type ‘‘clinical trial’’ with the drug name
mentioned, and the disease a major subject heading for that
article. Still not all 3,175 associations have an obvious MOA
explanation based on current knowledge. We thus include all of
the associations in Table S1 and look forward to further
experiments, and analysis. Based on these 3,175 associations, we
built Naı ¨ve Bayes models to predict the 145 indication endpoints
using their associated SEs as the features. The average AUCs of
10-fold cross validations for each of the 145 disease were
calculated using Weka [36]. 92% of the AUCs were above 0.8
(Table S3) suggesting that multiple SEs can be used to predict
indications.
Visualization of the disease-SE associations
Based on these 3,175 associations, a disease-SE network was
constructed (Fig. 1B). Diseases that share similar SEs tend to
cluster with each other. The diseases are grouped into three
clusters dominated by neuropsychiatric diseases (Fig. 1C),
circulatory system diseases, and neoplasms (Figure S1)a s
visualized using Cytoscape [37]. The neuropsychiatric disease-
dominated cluster (Fig. 1C) shares SEs, such as tardive dyskinesia,a n
involuntary movement SE associated with long term dosing or
high doses of antipsychotics [38]. Other SEs, such as priapism,a
painful medical condition in which the erect penis or clitoris does
not return to flaccid state [39], is also shared by four
neuropsychiatric diseases (Fig. 1D). For instance, the connection
between priapism and OCD suggests repositioning opportunities of
priapism compounds to OCD (Text S1).
DRoSEf for compounds in clinical trials
The prior analysis requires knowing the SEs from a drug’s label
before we predict new indications. For clinical candidates whose
SE information is unknown, we predicted their SEs based on the
compound structure and then predicted new indications based on
those SEs. We hypothesized that such a prediction ‘‘chain’’ would
provide mechanistic explanations of the compound’s new
indication based on the disease-SE association and the structural
information of the compound. We extracted all small molecules
from GenegoH MetaBase along with their disease indications [40].
This provided molecules in clinical trials in addition to the 888
SIDER drugs. These 4,200 molecules are indicated for at least one
of 101 diseases from the 145 disease set. MetaBase also uses MeSH
disease terms, thus making comparisons to the MeSH indications
from PharmGKB straightforward.
DRoSEf requires the side-effect profile for each molecule to
predict new indications. However, such information is difficult to
obtain for most of the 4,200 molecules because these are generally
clinical candidates without FDA approved drug labels, and have
little or no SEs published from their clinical trials in a standardized
way. Quantitative structure-activity relationship (QSAR) models
have been used to predict target binding of the ligand [41]. We
hypothesized that QSAR models could also be used to predict SEs.
We are mapping compound structure to possible SEs and then
onto a disease indication. For side effect j (SEj), we recruited the
positive set (w
pos
j , drugs listing SEj) and the negative set (w
neg
j , drugs
not reported to induce SEj) from the 888 SIDER drug set
Table 1. Some of the associations from the disease-SE network.
Disease Class Disease Side Effect MCC sn sp p value
Predictions (False Positive
Drugs)
a
Circulation System Stroke Positive ANA 0.46 0.47 0.98 1.8E-15 statins, ramipril
Other Transplantation Cytomegalovirus infection 0.75 0.75 0.99 3.5E-06 methotrexate
Metabolite disease Diabetes Mellitus Porphyria 0.44 0.50 0.98 8.8E-06 valproic acid, pyrazinamide,
naproxen, estradiol
Psychiatric disease Depressive Disorder Delusions 0.46 1.00 0.91 1.1E-08 cabergoline, memantine, pergolide
Psychiatric disease Depressive Disorder Hyperacusis 0.55 0.88 0.96 9.0E-09 phenytoin, modafinil
Neoplasms Neoplasms Constitutional symptoms 0.50 0.56 0.94 2.6E-18 nevirapine
aDrugs not listed treating disease (2
nd column) but listed the SE (3
rd column).
doi:10.1371/journal.pone.0028025.t001
Drug Repositioning Based on Side-Effects
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28025(Fig. 2A). For 566 of the 584 SEs, we successfully trained QSAR
models (18 of them failed). Then we used these 566 QSAR models
to predict the SEs of 4,200 molecules from MetaBase (Fig. 2B,
Methods S1).
T h eR O Cc u r v e so ft h ep r e d iction performance for 101
disease endpoints are shown in Figure S2,a n dt h e i rA U C sa r e
summarized in Table S4. Some of the disease endpoints had
only a few positive drugs from the MetaBase set, and their AUC
value might not accurately reflect the true performance. We,
therefore, focus on the diseases that have more than 30
compounds with that specific indication in MetaBase. Table 2
lists the diseases with AUC greater than 0.70. We then
evaluated the extent of the structure similarity information that
contributed to these performances. In fact, if we do not use the
SE information at all and rely only on chemical structure, only
18% of the 101 disease endpoints achieve AUCs above 0.7
(Table S4), while using DRoSEf 36% of disease endpoints had
AUCs above 0.7. Moreover, 74% of endpoints achieved higher
AUC than using chemical structural information alone. Only
2 2 %o ft h ev a r i a n c ei nt h eA U C so fD R o S E fw a se x p l a i n e db y
chemical structure across the 101 endpoints. This again
indicates that the side effect intermediate is adding value to
the prediction.
Case study of clinical molecules predicted to treat
hypertension
MetaBase includes 203 molecules indicated for hypertension.
However, there are additional molecules that have not yet been
reported to treat hypertension that achieved a relatively high H
score based on SEs (corresponding to the rightmost part of the
blue line in Fig. 3A). There are 12 SEs linked to hypertension that
meet our criteria from DRoSEf. The structure of some of the
molecules with the highest H and their predicted relationships
with the 12 hypertension-associated SEs are visualized in Fig. 3C.
Many of the SEs are physiologically linked to hypertension and the
MOA for some of the SEs matched published studies. Postural
hypotension is an obvious SE that might suggest hypertension as an
indication as it is the sudden drop in blood pressure that may
occur when a person stands up. Drugs causing this SE should at
least be considered and evaluated for treating hypertension
provided the effect can be controlled with formulation and dosing.
Nine of the top 10 molecules predicted to effect hypertension from
MetaBase are also predicted to induce postural hypotension, which is
perhaps a relevant clinical phenotypic screen for hypertension and
adds direct evidence for potential repositioning (Fig. 3C).
pemphigus is reported to be induced by angiotensin-converting
enzyme (ACE) inhibitors [42], and cold extremities is antihyperten-
Figure 2. A schematic figure of mapping drug structure to side effect and then onto a disease indication. a) Train the 566 SE models.
For SEj, the w
pos
j (+) and w
neg
j (2) were recruited from 888 SIDER molecules. b) The diseasei-moleculek association (Hik) was calculated as the dot
product value of the disease-SE association vector (DS) and SE-molecule association vector (SM). The binary SE-molecule (SM) association was
calculated from QSAR models. The width of the colored lines indicates the weights of the disease-SE associations. As an example, Hi2 is more than Hi1
as the association of side effect j in green to disease i is stronger.
doi:10.1371/journal.pone.0028025.g002
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could be further confirmed in SIDER dataset, where ACE
inhibitors were significantly enriched in drugs listing pemphigus
(p=5.7E-10) and b-blockers were associated with cold extremities
(p=4.5E-6). In our prediction results, we also found that ACE
inhibitors are significant enriched in the drugs predicted as
pemphigus positive (Fisher’s exact p=1.4E-3); whereas b-adrenergic
blockers have significantly higher frequency in drugs predicted as
cold extremities positive (p=0.02). Claudication or peripheral artery
disease, which includes narrowing and hardening of the arteries, is
a SE associated with hypertension treatment. A case report
demonstrated that reduction in blood pressure could worsen
intermittent claudication [44]. Sinus arrest can be induced by
antihypertensives [45]. ‘Sexual dysfunction’ is a known complica-
tion of some antihypertensive drug therapy and has been
associated with many of the antihypertensive agents [46].
Intracranial hypotension is the cause for arm pain from central
traction causing irritation of a cervical nerve [47]. However, we
did not identify obvious MOAs for the association of vasculitis,
tracheobronchitis and sialadenitis with the hypertension. In
summary, the exploration of the disease-specific SEs can provide
a more rational explanation for drug repositioning via under-
standing the known and unknown mechanism-of-action (MOA)
between the SEs and the drugs’ therapeutic effect.
As these are clinical molecules the amount of additional
published clinical data is limited, however there is still target
based validation for some of these molecules. Among the top
investigational molecules in Fig. 3C, glenvastatin is originally
indicated for hyperlipidemias. Studies have documented the effect
of statins on blood pressure [48]. Melagatran and ximelagatran are
thrombin inhibitors. Thrombin signaling was proved to be
involved in the vascular response to hypertension [49]. Muragli-
tazar is an agonist of PPARa and PPARc. PPARa stimulation
exerts a lowering effect in blood pressure [50]; whereas the SEs of
PPARc agonists usually include lowering of blood pressure [51].
ABT-770 is a metalloproteinase inhibitor, and the metalloprotei-
nase was reported to regulate blood pressure [52]. Blonanserin acts
as the antagonist of 5-HT2 receptor. A study demonstrated that
the increase in blood pressure is due to a stimulation of
postjunctional 5-HT2 receptors [53].
Discussion
This study proposes systematic drug repositioning based on the
rational association between diseases and SEs. We extracted 3,175
relationships between diseases and SEs. For some of the drug
repositioning opportunities, we found compelling published
clinical trials. However, there are many new indications which
have not been tested yet. We built Naı ¨ve Bayes models to predict
indications for 145 diseases using the SEs as features. The AUC
was above 0.8 in 92% of these models. We also extended the
method to predict indications for 4,200 clinical molecules by
utilizing QSAR models for SE. These results suggest that clinical
pharmacologists should pay even more attention to the SEs
observed in clinical trials, as they may suggest additional
indications for their drugs based on understanding the connections
between SEs and the therapeutic effect of the drug.
Assaf et al [54] systematically predicted the indication for drugs
based on multiple properties of drugs and diseases. However, our
focus on utilizing clinical phenotypic information enables
interpretability and direct application of findings. The examples
discussed in this study are primarily for demonstrating the
principle of this methodology, but all of them may not necessarily
be effective or practical for repositioning. Other factors need to be
considered for practical use of this methodology, such as the
unmet medical need for the disease, the fraction of the population
showing the side effect, the CNS penetration of the molecule, and
whether the therapeutic effect is significant enough in comparison
to current treatments. Moreover the previous therapeutic effect
could now become a potential side effect as well, and will need to
be carefully considered in the risk benefit profile. But, hopefully, in
a few cases this could all be managed via choosing a suitable
formulation, dose, and the sub population.
The SEs have been used to predict drug targets [4]. DRoSEf
mimics a phenotypic clinical assay rather than the target based
Table 2. AUCs for disease indications based on predicting side effects from structure, and then using side effects to predict the
indication.
Disease category Disease
a
# of drugs with this
indication in clinical trial
# of SE features
associated with disease AUC
Neuropsychiatric Depression 72 87 0.82
Depressive Disorder 42 204 0.82
Schizophrenia 77 55 0.81
Depressive Disorder, Major 48 170 0.81
Anxiety Disorders 144 186 0.71
Neoplasms Stomach Neoplasms 49 4 0.77
Carcinoma, Non-Small-Cell Lung 73 10 0.76
Lung Neoplasms 59 30 0.74
Neoplasms 347 42 0.74
Lymphoma 28 4 0.72
Leukemia, Myeloid, Acute 30 20 0.71
Head and Neck Neoplasms 33 7 0.70
Others Hypertension 203 12 0.74
Diabetes Mellitus, Type 2 112 8 0.71
aOnly diseases with AUC.0.7 are shown.
doi:10.1371/journal.pone.0028025.t002
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found using phenotypic screening than target-based approaches
between 1999 and 2008 [17]. Our study demonstrates that the
clinical phenotypic features work well in suggesting new
indications, and may even outperform in vitro assays or animal
models that face many translational challenges. In this study, we
did not consider the absolute frequency of the SEs or the relative
frequency or significance compared to placebo.
In SIDER, only 37.9% of the drug-SE pairs have frequency
information associated with them, thus to maximize the amount of
drugs covered we did not utilize frequency information. SEs with
higher frequencies like nausea and vomiting are usually described in
detail with frequency information and written in the drug label.
However, the frequencies for most of the informative SEs are
unknown. Some of the SEs in Table S1 are regarded to be rare,
but are still implicated in the pathogenesis of a particular disease.
In fact, they might expose an extreme phenotype. For example,
porphyria is a rare inherited disease [55]. Patients with this inherited
disease show a decrease in the risk of porphyria on becoming
diabetic [26,56]. This may suggest why antidiabetic drugs are
usually reported to worsen porphyria, but this may only affect
people with an inherited genetic mutation for porphyria, and this
subset of population may in theory act as the ‘‘model’’ for
screening anti-diabetes drugs, with porphyria as the screening
endpoint. Thus, a drug that increases porphyria in this sub
population with the mutation may well be a good diabetes drug
in a different larger population. So the off-phenotype of a drug on
a sub population might suggest its use for a broader population. In
addition to mimicking a human phenotypic screen to help fish out
positive candidates for repositioning, DRoSEf may also suggest the
unrecognized disease pathogenesis, such as studying porphyria may
lead to better understanding of the diabetes.
A limitation of DRoSEf is the number (888) of drugs with
available side effects. The models and accuracy would improve if
we were able to obtain side effects on a larger number of drugs.
Moreover, predictions of indications for 4,200 MetaBase drugs
would also be better if we had some side effect information from
their early stage clinical trials rather than relying on just their
structures. Even if we had to rely on structures for preclinical
molecules, it would help if the structure based side effect models
were trained on more than the 888 drugs from SIDER. The 888
molecules may not be representative in terms of structural
variability, and it is possible that some of the QSAR models are
over-fitted. Constructing a larger database of disease-SE associa-
Figure 3. Predict drugs’ repositioning potential for hypertension via DRoSEf. a) The distribution of the H score for the positive (red) and
negative (blue) set for hypertension. The molecules with high H score in negative set (red square bracket) were chosen as the candidates for treating
hypertension. b) The ROC curve of using H score to predict hypertension. The AUC is 0.74. c) Predicted relationships of the top molecules with the 12
SEs and the association of these SEs with the hypertension. The binary association among molecules and SEs is in grey lines. The association strength
between SE and disease is reflected in the color and the width of the edge. Postural hypotension is highlighted as the SE explicitly linked to
hypertension.
doi:10.1371/journal.pone.0028025.g003
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improve accuracy and help reduce over-fitting. On the other
hand, the prediction performance could also be an underesti-
mate. Molecules that have not yet been reported to treat a
disease may well be capable of treating that disease, and in
m a n yc a s e s( t h ef a l s ep o s i t i v ed r u g sa ss h o w ni nTable 1)
clinical trials have already shown a positive effect. These
molecules are classified as false positives currently, and this
decreases the computed AUC value. However, even with this
imperfect SE information and potentially underestimated
prediction performance, 36% of the disease endpoints achieved
AUCs higher than 0.7 (Table S3), which is generally higher
than the disease prediction performance using the QSAR model
alone. Although the reliability of the QSAR models needs to be
considered due to the limited number of drugs in the SIDER
set, the major aim of this study is not to demonstrate the power
of using the QSAR model, but to emphasize that the
performance of QSAR model is enhanced after incorporating
side-effect information.
Using multiple SEs features to predict the disease endpoint
could also improve sensitivity over individual features. Although
there are explicit individual disease-SE associations, not all of them
have sufficient prediction power. For instance, not all drugs
treating anemia list polycythemia as a SE, thus the sensitivity of this
feature is limited. The inclusion of multiple features could enhance
sensitivity. If a true positive is not recalled by an individual feature,
it may be suggested by other features. Thus better sensitivity could
be achieved if we had more SEs annotations or other phenotypic
terms from drug label. The emphasis on the sensitivity, however,
may affect specificity. To avoid this problem, all the SEs chosen for
the prediction have high specificity (sp.0.75, see Methods). The
false positives could be excluded further through testing on in vitro
and in vivo models.
DRoSEf provides numerous predictions based on the associa-
tion of the SE and the disease. It greatly benefits from the fact that
clinical side effects are human phenotypic data obviating
translation issues. The methodology for the first time offers the
possibility that the unfavorable side effects in a subpopulation can
themselves offer repositioning opportunities to positively impact a
broad range of patients.
Methods
Constructing the disease-side effect associations
The disease-SE associations were computed based on the
disease-drug association and drug-SE association, which were
extracted from PharmGKB and SIDER databases respectively.
PharmGKB uses MeSH term to describe diseases. For side effects
from SIDER, we only use them as present or absent in association
with a drug, and do not consider their frequencies explicitly, as
only 37.9% of the drugs had side effect frequencies associated with
them. Let true positive (tpij) be the number of drugs listing that are
indicated for disease i and list j as a SE; false positives (fpij) be the
number of drugs that are not indicated for disease i and list SE j;
true negatives (tnij) be the number of drugs that are not indicated
for disease i and do not list SE j; false negatives (fnij) be the number
of drugs that are indicated for i and do not list SE j. We calculated
the sensitivity (snij), specificity (spij) and Matthews correlation
coefficient or MCC (mccij) of using SE j to predict disease i using
the standard formulas below:
snij~tpij=(tpijzfnij),
spij~tnij=(fpijztnij),
mccij~(tpijtnij{fpijfnij)=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(tpijzfpij)(tpijzfnij)(fnijztnij)(fpijztpij)
p
:
For binary variables, the MCC is the equivalent of a Pearson
correlation coefficient. The two-sided Fisher’s exact pij value was
also calculated. A disease-SE association was considered to be non-
informative, if (pijw0:05jmccijv0:15jspijv0:75jtpijv2). This
threshold provided 3,175 informative associations including 145
MeSH disease phenotypes and 584 SEs. The Fisher’s p value here
is a measure of the association but not an accurate estimation of
the type I error as it is not corrected using the false discovery rate.
The associations in Table 1 were selected based on the following
criteria: the MCC is among the top 150 of all 3,175 associations
and tpijw3. From these we manually picked a few associations
that had strong literature support. In Fig. 1, to enhance the
visibility of the network layout, the disease-SE relationships were
not visualized if
(pijw0:05jmccijv0:20jspijv0:80jtpijv2):
Training the prediction models for clinical compounds
We calculated several structural descriptors (logP, molecular
weight, number of hydrogen bond donors and acceptors, number
of rotatable bonds and SCFP6 fingerprint) for 888 SIDER drugs.
We tried to train 584 SE models with multiple Laplacian-modified
Bayesian method [41] using the features above. 566 SE models
were successfully trained.
Predict the disease endpoints for clinical molecules
based on SEs
We evaluated 5,534 clinical candidates and marketed drugs
from Genego MetaBase (as of Jan. 2011). MetaBase uses the
MeSH disease ontology for drug indications. We considered only
molecules that included SMILES strings, and further listed a
disease indication matching at least one of the 145 diseases from
the SIDER set, and we excluded molecules that were in the 888
SIDER drug set. This left us with 4,200 small molecules. These
molecules were assigned at least one of the 101 disease MeSH
term that match the 145 MeSH diseases.
The endpoint of our prediction is whether or not the compound
should be considered for a clinical trial for treating disease i just
based on side effect information. For each disease i, we computed
its side-effectome profile vector from the SIDER data,
DSi~½dsi1,dsi2,:::,dsij ,j[½1,566 ,i[½1,101 ,
where dsij quantifies the association of disease i and SE j. The
vectors were generated using seven different metrics, i.e.,
dsij[ bij,mccij,mcc4
ij,snij,sn4
ij,spij,sp4
ij
no
,
where bij~0 if (pijw0:05jmccijv0:15jspijv0:75jtpijv2), else,
bij~1. We used the exponent four in an effort to enhance the
signal of the high MCC, sn or sp.
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effectome profile vector SMk by computing it using each of the
566 pre-trained SE QSAR models,
SMk~½sm1k,sm2k,:::,smjk ,j[½1,566 ,k[½1,4200 ,
where smjk~1 if the molecule k is predicted as possibly causing SE
j, else smjk~0. We calculate the association Hik between disease i
and molecule k as the dot product of the two vectors,
Hik~SDSij,SMjkT~
X 566
j~1
dsijsmjk
We compute Hik using each of the seven metrics, and for each
metric we further computed an AUC for each of the 101
endpoints. The metrics sn4
ij performed best among all metrics in
terms of the mean AUC across all 101 disease endpoints. Thus, the
AUC value in Table S4 is based on the sn4
ij metrics.
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